Tempus AI Stock Price, News & Analysis

Tempus AI (NASDAQ: TEM) has announced the acquisition of Deep 6 AI, a leading AI-powered precision research platform. Deep 6 AI's network spans over 750 provider site locations and more than 30 million patients, which will significantly expand Tempus' existing infrastructure.

Deep 6 AI specializes in clinical trial optimization, patient recruitment acceleration, and real-world evidence generation. Their AI software matches patients to clinical trials by analyzing real-time structured and unstructured EMR data across various healthcare institutions, including academic medical centers, NCI-Designated Cancer Centers, and NCI Community Oncology Research Programs.

The acquisition aims to enhance Tempus' connectivity efforts and strengthen its ability to deploy critical applications like Next (for closing care gaps) and TIME (for matching patients to clinical trials).

Tempus AI (NASDAQ: TEM) reported strong Q4 2024 results with revenue increasing 35.8% year-over-year to $200.7 million. The company's Genomics segment generated $120.4 million (+30.6% YoY), while Data and services reached $80.2 million (+44.6% YoY).

Q4 gross profit grew 49.7% to $122.1 million, with net loss improving to ($13.0 million) from ($50.5 million) in Q4 2023. For full year 2024, revenue increased 30.4% to $693.4 million, with Genomics contributing $451.7 million and Data services $241.6 million.

The company completed the Ambry Genetics acquisition on February 3, 2025, and received FDA approval for xT CDx diagnostic device with a $4,500 reimbursement rate. Tempus projects 2025 revenue of $1.24 billion (+79% growth) and expects positive Adjusted EBITDA of $5 million, marking a $110 million improvement over 2024.

Tempus AI (NASDAQ: TEM) and Genialis have announced a multi-year collaboration to develop new RNA-based algorithms for cancer treatment. Genialis will utilize Tempus' multimodal dataset to validate their AI foundation model, the Genialis™ Supermodel, which was developed using ~1 million RNA-sequencing samples.

Through this partnership, Genialis gains access to Tempus' Lens analytics platform, providing de-identified multimodal patient records to validate biomarker signatures. Tempus receives rights to evaluate and potentially license Genialis-developed algorithms for their xR platform.

The collaboration has already yielded results with Genialis™krasID, the first commercial algorithm predicting patient response to KRAS-targeted therapies across cancer types. This algorithm, validated using Tempus' data, effectively stratifies patients into response groups based on their likelihood of treatment success.

Tempus AI (NASDAQ: TEM) has announced its participation in the TD Cowen 45th Annual Health Care Conference, scheduled for March 3-5, 2025, in Boston, MA. The company's Chief Financial Officer, Jim Rogers, will engage in a fireside discussion on Monday, March 3. The event will be accessible to viewers through a live webcast.

Tempus, which specializes in leveraging artificial intelligence for precision medicine and patient care advancement, will use this platform to share insights about their technology and healthcare initiatives.

Ares Management (NYSE: ARES) has expanded its debt financing for Tempus AI (NASDAQ: TEM) with an additional $300 million, bringing the total debt package to $560 million. The new financing supports Tempus' recent acquisition of Ambry Genetics, which closed on February 3, 2025.

Tempus, founded in 2015, specializes in implementing AI solutions in healthcare, focusing on clinical care and research products. The company's integrated business model includes patient sequencing, data collection through licensing and analytical tools, and diagnostic testing insights across oncology, cardiology, pathology, and radiology.

This financing demonstrates Ares' capability to provide scalable capital to both non-sponsor-backed and sponsor-backed borrowers, with Ares expressing confidence in Tempus' growth strategy and the strategic acquisition of Ambry.

Tempus AI (NASDAQ: TEM) has announced its participation in the upcoming Morgan Stanley Technology, Media & Telecom Conference scheduled for March 3-6, 2025, in San Francisco, CA. The company's Founder and CEO, Eric Lefkofsky, will engage in a fireside discussion on March 3, 2025. The event will be accessible to viewers through a live webcast.

Tempus, which specializes in leveraging AI technology for precision medicine and patient care advancement, will use this platform to share insights about their operations and innovations. This participation represents an important opportunity for investors and stakeholders to gain direct insights into the company's strategies and developments.

Tempus AI (NASDAQ: TEM) announced a collaboration with the Institute for Follicular Lymphoma Innovation (IFLI) to develop a real-world multimodal, deidentified follicular lymphoma (FL) data library within Tempus' Lens platform. The initiative aims to accelerate the development of targeted therapies for FL patients through AI-driven insights.

The collaboration will initially focus on generating multimodal FL data for POD24 patients - those experiencing disease progression within 24 months of treatment - through a Tempus-sponsored study. The data library is expected to enhance researchers' understanding of FL biology and support the development of precision medicines by providing insights into the disease's heterogeneity.

The partnership combines IFLI's specialized FL focus with Tempus' AI-enabled solutions to create a centralized database that will be accessible to researchers and professionals working to combat follicular lymphoma.

Tempus AI (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has scheduled its fourth quarter and full year 2024 financial results announcement for Monday, February 24, 2025. The earnings conference call will be held at 4:30 p.m. ET on the same day.

The call will feature presentations from CEO Eric Lefkofsky and CFO Jim Rogers. Investors can access the live audio webcast through Tempus' Investor Relations website's events page or join via phone using the provided domestic (888-596-4144) and international (646-968-2525) dial-in numbers with Conference ID: 9601821.

Tempus AI (NASDAQ: TEM) has completed its acquisition of Ambry Genetics, a genetic testing company focused on understanding genetics-disease relationships. The transaction, valued at $600 million total, consists of $375 million in cash and $225 million in shares, with $100 million subject to a one-year lock-up period. The acquisition was financed by Ares Management Credit funds.

Tempus CEO Eric Lefkofsky emphasized that this strategic acquisition enhances their capability to deliver advanced solutions to clinicians, patients, and life sciences companies by combining diagnostics and data. Ambry Genetics will continue operating as a wholly-owned subsidiary of Tempus, maintaining its current leadership team.